NASDAQ:SBBP Strongbridge Biopharma (SBBP) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free SBBP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.95▼$2.0650-Day Range$1.89▼$2.2952-Week Range$1.85▼$4.26Volume684,684 shsAverage Volume866,464 shsMarket Capitalization$135.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Strongbridge Biopharma alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Strongbridge Biopharma Stock (NASDAQ:SBBP)Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide SBBP Stock News HeadlinesFebruary 10, 2024 | investing.comMatinas BioPharma Holdings Inc (MTNB)November 15, 2023 | lse.co.ukLytix Biopharma As Share Price (LYTIX.OL)May 3, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.November 4, 2023 | morningstar.comAmbrx Biopharma Inc AMAMAugust 19, 2023 | seekingalpha.comHILS Hillstream BioPharma, Inc.July 1, 2023 | finance.yahoo.comABUS - Arbutus Biopharma CorporationApril 25, 2023 | thestreet.comThe Nominees for Best Biopharma CEO of 2015 Are...January 11, 2023 | marketwatch.comDay One Biopharma Shares Rise 13% After Positive Topline Results for TovorafenibMay 3, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.September 22, 2022 | markets.businessinsider.comAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and PatientsSeptember 23, 2021 | apnews.comStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...September 23, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.September 14, 2021 | stockhouse.comXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaSeptember 9, 2021 | apnews.comStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...August 31, 2021 | apnews.comLeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...August 31, 2021 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With XerisAugust 5, 2021 | sfgate.comStrongbridge Biopharma: Q2 Earnings SnapshotAugust 5, 2021 | finance.yahoo.comStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateAugust 2, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy StatementJuly 29, 2021 | finance.yahoo.comStrongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021July 29, 2021 | finance.yahoo.comStrongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in IssueJuly 28, 2021 | nasdaq.comStrongbridge Biopharma's (NASDAQ:SBBP) Stock Price Has Reduced 48% In The Past Three YearsJuly 27, 2021 | finance.yahoo.comStrongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseJuly 27, 2021 | apnews.comStrongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with ...July 26, 2021 | msn.comBRIEF-Strongbridge Biopharma Plc, Unit, Avenue Venture Opportunities Fund Enter Amendment To A Term Loan AgreementSee More Headlines Receive SBBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2021Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SBBP CUSIPN/A CIK1634432 Webwww.strongbridgebio.com Phone(610) 254-9200FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,080,000.00 Net Margins-115.67% Pretax MarginN/A Return on Equity-66.82% Return on Assets-36.21% Debt Debt-to-Equity Ratio0.38 Current Ratio3.00 Quick Ratio2.95 Sales & Book Value Annual Sales$30.73 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book2.04Miscellaneous Outstanding Shares67,829,000Free FloatN/AMarket Cap$135.66 million OptionableOptionable Beta1.58 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesJohn H. JohnsonChief Executive Officer & DirectorRichard S. KollenderPresident & Chief Financial OfficerFredric CohenChief Medical OfficerBrian ConnerChief Compliance OfficerPeter J. ValentinssonSenior Vice President-Global Technical OperationsKey CompetitorsInterCureNASDAQ:INCRCoya TherapeuticsNASDAQ:COYAVistagen TherapeuticsNASDAQ:VTGNI-MabNASDAQ:IMABSyros PharmaceuticalsNASDAQ:SYRSView All Competitors SBBP Stock Analysis - Frequently Asked Questions How were Strongbridge Biopharma's earnings last quarter? Strongbridge Biopharma plc (NASDAQ:SBBP) released its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The biotechnology company earned $10.04 million during the quarter, compared to analyst estimates of $8.83 million. Strongbridge Biopharma had a negative net margin of 115.67% and a negative trailing twelve-month return on equity of 66.82%. What other stocks do shareholders of Strongbridge Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB). This page (NASDAQ:SBBP) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Strongbridge Biopharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
